When was Delfi Diagnostics founded?

Delfi Diagnostics was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Delfi Diagnostics located?

Delfi Diagnostics is headquartered in Baltimore, United States. It is registered at 1999 BRYAN ST STE 900,DALLAS,TX,75201,57.

Who is the current CEO of Delfi Diagnostics?

Susan Tousi of Delfi Diagnostics.

Which legal entities is Delfi Diagnostics associated with?

Delfi Diagnostics is associated with DELFI DIAGNOSTICS, INC..

How many employees does Delfi Diagnostics have?

As of May 31, 2026, the latest employee count at Delfi Diagnostics is 159.

Is Delfi Diagnostics a funded company?

Delfi Diagnostics is a funded company, having raised a total of $332M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 18, 2018.

When was the latest funding round of Delfi Diagnostics?

Delfi Diagnostics' latest funding was a $***** Conventional Debt round on Dec 01, 2025, with participation from 0 investor.

Where does Delfi Diagnostics rank among its competitors?

Delfi Diagnostics ranks 9th amongst 508 active competitors, of which 152 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Delfi Diagnostics, which secured $34.3M in Dec, 2025.

Who are the top competitors of Delfi Diagnostics?

Delfi Diagnostics' top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Delfi Diagnostics secured the most recent funding round in December, 2025.

Delfi Diagnostics - 2026 Company Profile, Team, Funding & Competitors

Delfi Diagnostics is a series B company based in Baltimore (United States), founded in 2019 by Victor Velculescu. It operates as a Provider of DNA sequencing for cancer detection. Delfi Diagnostics has raised $332M in funding from investors like Orbimed, DFJ Growth and Merck Global Health Innovation Fund. The company has 508 active competitors, including 152 funded and 115 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.

Company Details

Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Website: delfidiagnostics.com
Social
Email ID: *****@delfidiagnostics.com
Phone Number: +1 **********
Registered Address: 1999 BRYAN ST STE 900,DALLAS,TX,75201,57

Key Metrics

Founded Year

2019

Location

Baltimore, United States

Stage

Series B

Total Funding

$332M in 6 rounds

Latest Funding Round

Conventional Debt, Dec 01, 2025, $*****

Investors

Orbimed & 20 more

Ranked

9^th among 508 active competitors

Employee Count

159 as on May 31, 2026

Similar Companies

Guardant Health & 633 more

View Delfi Diagnostics' full profile

Delfi Diagnostics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
DELFI DIAGNOSTICS, INC. CIN: 32089374113 , United States, Active	Apr 11, 2023	-	-	-

Delfi Diagnostics has raised a total funding of $332M over 6 rounds. Its first funding round was on Jun 18, 2018. Delfi Diagnostics has 21 institutional investors.

Here is the list of recent funding rounds of Delfi Diagnostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 01, 2025	7804275	Conventional Debt	3118403	7760298	6280518	3797797
Jun 05, 2024	2690144	Series B	6752040	7086463	9714758	5380220
Jul 18, 2022	4531908	Series B	5903480	9656961	DFJ Growth	Lilly & 11 more

Access funding benchmarks and valuations. Sign up today!

View details of Delfi Diagnostics's funding rounds and investors

The founders of Delfi Diagnostics is Victor Velculescu. Susan Tousi is the CEO of Delfi Diagnostics.

Here are the details of Delfi Diagnostics' key team members:

Victor Velculescu: Founder and Board of Directors of Delfi Diagnostics. They serve on the board of 1 company.
Susan Tousi: CEO of Delfi Diagnostics.
Contact Info: 1 email address

Delfi Diagnostics' Board of Directors

Delfi Diagnostics's board has 13 active members. Justin Kao, Victor Velculescu, William Stevens, Rishi Gupta, Greg Yap, Peter Bach, Michael Dybbs, William J. Stevens, Jennifer Buechel, Douglas Schenkel, Nicholas Dracopoli, Jacob Van Naarden and Elizabeth Homans are independent board members.

Here is the list of Delfi Diagnostics' board of directors:

Name	Type	Representing	Status	Duration
Justin Kao	Independent board member	-	Current	3y 10m
easwabm	Independent board member	-	Current	1y 9m
qixkcph	Independent board member	-	Current	8y 8m
nqtgtww	Independent board member	-	Current	4y 4m
s{gbnnf	Independent board member	-	Current	5y 5m
zmmxsqd	Independent board member	-	Current	3y 4m
agckrup	Independent board member	-	Current	3y 9m
cqdegut	Independent board member	-	Current	5y 5m
cvcvyfr	Independent board member	-	Current	2y 6m
vkqigzi	Independent board member	-	Current	3y 3m
bnneqwb	Independent board member	-	Current	5y 3m
{otonxw	Independent board member	-	Current	7y 4m
{qloc{g	Independent board member	-	Current	9y 8m

View details of Delfi Diagnostics's Founder profiles and Board Members

Delfi Diagnostics' employee count trend

Delfi Diagnostics has 159 employees as of May 26. Here is Delfi Diagnostics's employee count trend over the years:

Employee count trend for Delfi Diagnostics

Uncover Delfi Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Delfi Diagnostics include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Delfi Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Sequoia Capital, SoftBank Vision Fund & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Sequoia Capital, HHS & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, HHS & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Kleiner Perkins, Roche & 11 others	71/100
5th	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Bank of America, Flagship Pioneering & 8 others	71/100
6th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Braidwell, Sixth Street & 19 others	71/100
7th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Ping An Ventures, Beyond Ventures & 21 others	70/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Neotribe & 31 others	69/100
9th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	Lilly, Illumina Ventures & 19 others	68/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Civilization Ventures, Bluebird Ventures & 6 others	66/100